Pathophysiology of L-dopa-induced dyskinesias

Movement Disorders

Volumn 14, Issue SUPPL. 1, 1999, Pages 4-8

  Bédard, Paul J ^a,b   Blanchet, Pierre J ^a   Lévesque, Daniel ^a   Soghomonian, Jean Jacques ^a   Grondin, Richard ^a   Morissette, Marc ^a   Goulet, Martin ^a   Calon, Frédéric ^a   Falardeau, Pierre ^a   Gomez Mancilla, Balthazar ^a   Doucet, Jean Pierre ^c   Robertson, George S ^c   DiPaolo, Thérèse ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROPEPTIDE; U 91356A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BASAL GANGLION; CONFERENCE PAPER; DYSKINESIA; HUMAN; IMMEDIATE EARLY GENE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; BINDING, COMPETITIVE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; GLOBUS PALLIDUS; HAPLORHINI; HUMANS; LEVODOPA; NEURAL PATHWAYS; NEURONS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, GABA; SUBSTANTIA NIGRA;

EID: 0242715531     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Nutt JG, Holford NH. The response to L-dopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39:561-573.
2. Blanchet PJ, Allard P, Grégoire L, et al. Risk factors for peak dose dyskinesias in 100 L-dopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193.
3. Bédard PJ, Di Paolo T, Falardeau P, et al. Chronic treatment with L-dopa, but not bromocriptine induces dyskinesias in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 1986;379:294-299.
4. Falardeau P, Bouchard S, Bédard PJ, et al. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150:59-66.
5. Rascol A, Guiraud B, Montastruc JL, et al. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150.
6. Gomez-Mancilla B, Bédard PJ. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 1992;117:185-188.
7. Blanchet PJ, Calon F, Martel JC. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859.
8. Guttman M, Seeman P. L-Dopa reverses the elevated density of D2 dopamine receptors in Parkinson's disease striatum. J Neural Transm 1985;64:93-103.
9. Morissette M, Goulet M, Calon F, et al. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Mol Pharmacol 1996;50:1073-1079.
10. Goulet M, Grondin R, Blanchet PJ. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res 1996;719:129-137.
11. Goulet M, Morissette M, Calon F, et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience 1997;79:497-507.
12. Marcotte ER, Sullivan RM, Mishra RK. Striatal G-proteins: effects of unilateral 6-hydroxydopamine lesions. Neurosci Lett 1994;169: 195-198.
13. Bordet R, Ridray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanisms of behavioral sensitization to L-dopa. Proc Natl Acad Sci USA 1997;94:3363-3367.
14. Morissette M, Goulet M, Grondin R. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 1998;10(suppl):2565-2573.
15. Herrero MT, Augood SJ, Hirsch EC. Effects of L-dopa on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 1995;68:1189-1198.
16. Jolkkonen J, Jenner P, Marsden CD. L-Dopa reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res Mol 1995;32:297-307.
17. Morissette M, Goulet M, Soghomonian JJ. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-dopa therapy. Brain Res Mol Brain Res 1997;49:55-62.
18. Zeng BY, Jolkkonen J, Jenner P. Chronic L-dopa treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience 1995;66:19-28.
19. Soghomonian JJ, Pedneault S, Blanchet PJ, et al. L-Dopa regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys. Brain Res Mol Brain Res 1996;39:237-240.
20. Calon F, Goulet M, Blanchet PJ, et al. L-Dopa or D2 agonist induced dyskinesias in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res 1995;680:43-52.
21. Hiroi N, Marek GJ, Brown JR, et al. Essential role of the FosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures. J Neurosci 1998;18:6952-6962.
22. Chen J, Kelz MB, Hope BT, et al. Chronic Fos-related antigens: stable variants of deltaFosB induced in brain by chronic treatments. J Neurosci 1997;17:4933-4941.
23. Hiroi N, Graybiel AM. Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum. J Comp Neurol 1996;374:70-83.
24. Vallone D, Pellecchia MT, Morelli M, et al. Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. Brain Res Mol Brain Res 1997;52:307-317.
25. Doucet JP, Nakabeppu Y, Bédard PJ, et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of ΔFosB-like proteins(s) in both the rodent and primate striatum. Eur J Neurosci 1996;8:365-381.
26. Maneuf YP, Mitchell IJ, Crossman AR, et al. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 1994;125:65-71.